Floatz Rating
D30/100
Confidence
Indicative
Sponsor
St. Olavs Hospital
Modality
Cell therapy
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06855121CT.gov The Norwegian Immunotherapy in Multiple Myeloma Study | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · AL Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ciltacabtagene Autoleucel (this asset) | St. Olavs Hospital | Unk | D · 30 |
| Dexasone | St. Olavs Hospital | P3 | BB |
| Cyclophosphamide | Alexion Pharmaceuticals, Inc. | P3 | B |
| Florbetaben | University of Zurich | P3 | B |
| Selinexor | Washington University School of Medicine | P2 | B |
| Bortezomib | Alexion Pharmaceuticals, Inc. | P3 | B |
| Melphalan | M.D. Anderson Cancer Center | P2 | B |
| Birtamimab | Prothena Biosciences Ltd. | P2 | B |
| Anselamimab | Alexion Pharmaceuticals, Inc. | P3 | B |
+14 more in the AL Amyloidosis cohort
Other indications for Ciltacabtagene Autoleucel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Smoldering Plasma Cell Myeloma | — | P2 | CCC · 53 |
| Plasma Cell Myeloma | — | P2 | CCC · 50 |
| Plasma Cell Leukemia | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ciltacabtagene Autoleucel in AL Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ciltacabtagene-autoleucel-al-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →